These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 24337647

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option.
    Saxena A, Bester L, Chua TC, Chu FC, Morris DL.
    Ann Surg Oncol; 2010 Feb; 17(2):484-91. PubMed ID: 19876691
    [Abstract] [Full Text] [Related]

  • 6. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
    Klingenstein A, Haug AR, Zech CJ, Schaller UC.
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
    [Abstract] [Full Text] [Related]

  • 7. Radioembolization in patients with hepatic metastases from breast cancer.
    Jakobs TF, Hoffmann RT, Fischer T, Stemmler HJ, Tatsch K, La Fougere C, Murthy R, Reiser MF, Helmberger TK.
    J Vasc Interv Radiol; 2008 May; 19(5):683-90. PubMed ID: 18440456
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases.
    Saxena A, Chua TC, Bester L, Kokandi A, Morris DL.
    Ann Surg; 2010 May; 251(5):910-6. PubMed ID: 20395859
    [Abstract] [Full Text] [Related]

  • 12. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
    D'Avola D, Lñarrairaegui M, Bilbao JI, Martinez-Cuesta A, Alegre F, Herrero JI, Quiroga J, Prieto J, Sangro B.
    Hepatogastroenterology; 2009 May; 56(96):1683-8. PubMed ID: 20214218
    [Abstract] [Full Text] [Related]

  • 13. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
    Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, Palmedo H, Overton C, Jones B, Salem R.
    Am J Clin Oncol; 2008 Jun; 31(3):271-9. PubMed ID: 18525307
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, Ashoori N, Reiser MF, Jakobs TF.
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
    Gunduz S, Ozgur O, Bozcuk H, Coşkun HS, Ozdogan M, Erkilic M, Sindel T, Yldlzs A, Ylmaz S, Boz A, Aydin F, Karayalçin B, Savas B.
    Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
    [Abstract] [Full Text] [Related]

  • 20. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres.
    Mulcahy MF, Lewandowski RJ, Ibrahim SM, Sato KT, Ryu RK, Atassi B, Newman S, Talamonti M, Omary RA, Benson A, Salem R.
    Cancer; 2009 May 01; 115(9):1849-58. PubMed ID: 19267416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.